Key Takeaways:
UBS upgraded MEDBOT-B (2252.HK) to 'Buy' from 'Neutral' and raised its price target by 68% to HKD35.9, citing surging overseas sales for its surgical robots.
"The company's focus on developing markets is a key differentiator," the UBS report said, highlighting a 287% year-over-year increase in overseas revenue.
The upgrade was underpinned by the strong performance of MEDBOT-B's Toumai surgical robot, which saw sales volume increase more than fivefold. The company is targeting markets in South America, South Asia, and Central and Eastern Europe, where the penetration of surgical robots is low. UBS estimates these regions have a cumulative installation demand for more than 10,000 laparoscopic surgical robots, with MEDBOT-B positioned to capture a 25% market share.
MEDBOT-B aims to double its total revenue in 2026 from 2025 and increase its overseas revenue contribution to over 80% from 73% last year. The company expects to reach breakeven in the first half of 2026, a goal UBS finds achievable based on the current trajectory. The new price target from UBS implies a significant upside from the previous target of HKD21.4.
The positive outlook from UBS is a significant development for MEDBOT-B, potentially boosting investor confidence and attracting further institutional investment. The company's strategy of targeting less-penetrated developing markets appears to be paying off, setting it apart from competitors focused on developed nations.
This article is for informational purposes only and does not constitute investment advice.
